PO-32: Rivaroxaban targets the hypercoagulant tumour microenvironment to reduce primary tumour growth and stem cell activity in oestrogen receptor positive breast cancer murine models. Issue 213 (May 2022)

Record Type:: Journal Article
Title:: PO-32: Rivaroxaban targets the hypercoagulant tumour microenvironment to reduce primary tumour growth and stem cell activity in oestrogen receptor positive breast cancer murine models. Issue 213 (May 2022)
Main Title:: PO-32: Rivaroxaban targets the hypercoagulant tumour microenvironment to reduce primary tumour growth and stem cell activity in oestrogen receptor positive breast cancer murine models
Authors:: Blower, E.L.
Castle, J.
Santiago-Gomez, A.
Clarke, R.B.
Kirwan, C.C.
Abstract:
Is Part Of:: Thrombosis research. Issue 213(2022)Supplement 2
Journal:: Thrombosis research
Issue:: Issue 213(2022)Supplement 2
Issue Display:: Volume 213, Issue 2 (2022)
Year:: 2022
Volume:: 213
Issue:: 2
Issue Sort Value:: 2022-0213-0002-0000
Page Start:: S25
Page End:
Publication Date:: 2022-05
Subjects:: Thrombosis -- Periodicals
616.135
Journal URLs:: http://www.sciencedirect.com/science/journal/00493848 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0049-3848(22)00222-5 ↗
Languages:: English
ISSNs:: 0049-3848
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 8820.365000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 21574.xml